David M Kent1, Robin Ruthazer, Harry P Selker. 1. Division of Clinical Care Research, Tufts-New England Medical Center, Boston, Mass 02111, USA. dkent1@lifespan.org
Abstract
BACKGROUND AND PURPOSE: Recombinant tissue plasminogen activator (rtPA) has been demonstrated to improve outcomes in acute ischemic stroke when delivered within 3 hours of symptom onset. However, the Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke (ATLANTIS B) trial, in which patients were treated mostly between 3 and 5 hours after symptom onset, found no overall benefit from rtPA. We hypothesized that a subgroup of patients at low risk for thrombolysis-related intracranial hemorrhage, identifiable on the basis of pretreatment clinical variables, may benefit even when treated after 3 hours, despite the overall results of the trial. METHODS: Using an independently derived multivariate model that predicts the risk of thrombolysis-related intracranial hemorrhage in patients receiving tPA for acute myocardial infarction (based on 6 easily obtainable clinical characteristics), we stratified patients in the ATLANTIS B trial into low-, intermediate-, and high-risk tertiles. We examined outcomes in the prespecified low-risk subgroup using a global test of significance across 4 outcome scales. RESULTS: Despite having a similar average baseline stroke severity and median time to treatment (270 minutes), patients in the prespecified low-risk group (n=194) were significantly less likely to have a symptomatic intracranial hemorrhage than other patients in the trial (2.2% versus 9.2%, P=0.03). Although there was no treatment effect for rtPA in the overall trial, a consistent trend favoring rtPA therapy (a 5% to 12% absolute treatment benefit) was found across 4 different stroke scales in the prespecified low-risk group (P=0.10). The treatment-benefit-by-risk interaction was significant (P=0.03). CONCLUSIONS: Use of a multivariate index based on clinical variables is a promising approach to assist in the selection of patients with a favorable risk-benefit profile for thrombolytic therapy beyond 3 hours.
BACKGROUND AND PURPOSE: Recombinant tissue plasminogen activator (rtPA) has been demonstrated to improve outcomes in acute ischemic stroke when delivered within 3 hours of symptom onset. However, the Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke (ATLANTIS B) trial, in which patients were treated mostly between 3 and 5 hours after symptom onset, found no overall benefit from rtPA. We hypothesized that a subgroup of patients at low risk for thrombolysis-related intracranial hemorrhage, identifiable on the basis of pretreatment clinical variables, may benefit even when treated after 3 hours, despite the overall results of the trial. METHODS: Using an independently derived multivariate model that predicts the risk of thrombolysis-related intracranial hemorrhage in patients receiving tPA for acute myocardial infarction (based on 6 easily obtainable clinical characteristics), we stratified patients in the ATLANTIS B trial into low-, intermediate-, and high-risk tertiles. We examined outcomes in the prespecified low-risk subgroup using a global test of significance across 4 outcome scales. RESULTS: Despite having a similar average baseline stroke severity and median time to treatment (270 minutes), patients in the prespecified low-risk group (n=194) were significantly less likely to have a symptomatic intracranial hemorrhage than other patients in the trial (2.2% versus 9.2%, P=0.03). Although there was no treatment effect for rtPA in the overall trial, a consistent trend favoring rtPA therapy (a 5% to 12% absolute treatment benefit) was found across 4 different stroke scales in the prespecified low-risk group (P=0.10). The treatment-benefit-by-risk interaction was significant (P=0.03). CONCLUSIONS: Use of a multivariate index based on clinical variables is a promising approach to assist in the selection of patients with a favorable risk-benefit profile for thrombolytic therapy beyond 3 hours.
Authors: Susanna F Fustolo-Gunnink; Karin Fijnvandraat; David van Klaveren; Simon J Stanworth; Anna Curley; Wes Onland; Ewout W Steyerberg; Ellen de Kort; Esther J d'Haens; Christian V Hulzebos; Elise J Huisman; Willem P de Boode; Enrico Lopriore; Johanna G van der Bom Journal: Blood Date: 2019-12-26 Impact factor: 22.113
Authors: John R Sims; Guy Rordorf; Eric E Smith; Walter J Koroshetz; Michael H Lev; Ferdinando Buonanno; Lee H Schwamm Journal: AJNR Am J Neuroradiol Date: 2005-02 Impact factor: 3.825
Authors: Andrew K Ottens; Liliana Bustamante; Erin C Golden; Changping Yao; Ronald L Hayes; Kevin K W Wang; Frank C Tortella; Jitendra R Dave Journal: J Neurotrauma Date: 2010-10-09 Impact factor: 5.269
Authors: Nicole B Gabler; Naihua Duan; Diana Liao; Joann G Elmore; Theodore G Ganiats; Richard L Kravitz Journal: Trials Date: 2009-06-19 Impact factor: 2.279